It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Tumor-associated myeloid-derived cells (MDCs) significantly impact cancer prognosis and treatment responses due to their remarkable plasticity and tumorigenic behaviors. Here, we integrate single-cell RNA-sequencing data from different cancer types, identifying 29 MDC subpopulations within the tumor microenvironment. Our analysis reveals abnormally expanded MDC subpopulations across various tumors and distinguishes cell states that have often been grouped together, such as TREM2+ and FOLR2+ subpopulations. Using deconvolution approaches, we identify five subpopulations as independent prognostic markers, including states co-expressing TREM2 and PD-1, and FOLR2 and PDL-2. Additionally, TREM2 alone does not reliably predict cancer prognosis, as other TREM2+ macrophages show varied associations with prognosis depending on local cues. Validation in independent cohorts confirms that FOLR2-expressing macrophages correlate with poor clinical outcomes in ovarian and triple-negative breast cancers. This comprehensive MDC atlas offers valuable insights and a foundation for futher analyses, advancing strategies for treating solid cancers.
Tumour-associated myeloid cells have been linked to patient outcome and treatment response in multiple cancer types. Here, the authors use deconvolution of single cell RNA-sequencing data to identify myeloid populations which are prognostic across cancer types.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 Brazilian National Cancer Institute (INCA), Laboratory of Bioinformatics and Computational Biology, Division of Experimental and Translational Research, Rio de Janeiro, Brazil (GRID:grid.419166.d)
2 Federal University of Santa Catarina, Department of Microbiology, Immunology, and Parasitology, Florianópolis, Brazil (GRID:grid.411237.2) (ISNI:0000 0001 2188 7235)
3 University of São Paulo,(USP), Department of Immunology, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
4 University of São Paulo,(USP), Department of Immunology, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); Instituto D’Or de Ensino e Pesquisa, São Paulo, Brazil (GRID:grid.472984.4); University of São Paulo (USP), Department of Medicine, Division of Molecular Medicine, Laboratory of Medical Investigation 29, School of Medicine, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
5 University of São Paulo,(USP), Department of Immunology, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); Instituto D’Or de Ensino e Pesquisa, São Paulo, Brazil (GRID:grid.472984.4); University of São Paulo (USP), Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Departament of Hematology and Cell Therapy, Hospital das Clínicas HCFMUSP, School of Medicine, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
6 Brazilian National Cancer Institute (INCA), Division of Pathology, Rio de Janeiro, Brazil (GRID:grid.419166.d)
7 Brazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development, Rio de Janeiro, Brazil (GRID:grid.419166.d)
8 Brazilian National Cancer Institute (INCA), Division of Clinical Research and Technological Development, Rio de Janeiro, Brazil (GRID:grid.419166.d); Brazilian National Cancer Institute (INCA), Gynecologic Oncology Section, Rio de Janeiro, Brazil (GRID:grid.419166.d)
9 Universidade Estadual de Campinas, Laboratory of Immunometabolism, Department of Genetics, Evolution, Microbiology, and Immunology, Institute of Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)
10 Universidade Estadual de Campinas, Obesity and Comorbidities Research Center (OCRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Experimental Medicine Research Cluster (EMRC), Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494); Universidade Estadual de Campinas, Laboratory of Aging Biology, Department of Biochemistry and Tissue Biology, Campinas, Brazil (GRID:grid.411087.b) (ISNI:0000 0001 0723 2494)